Early clinical data on BGB-3111 encouraging - National
Publish Date: 2/11/2016
Early results from a phase I clinical trial using BGB-3111 – a new treatment for relapsed non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia (CLL) – shows the drug is well tolerated and effective as a single-agent therapy.
CLL Australian Research Consortium Forum – Sydney - September 2016 - National
Publish Date: 22/8/2016
Ongoing research is resulting in monumental and rapid change in chronic lymphocytic leukaemia (CLL), the most commonly diagnosed leukaemia in adults in Australia and other western countries. The CLL Australian Research Consortium (CLL ARAC) Forum 2016 is the perfect opportunity for health professionals to be updated on CLL and Australian clinical trials.